SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today announced the launch of the t:connect® HCP Portal. The portal is an extension of the company’s Mac- and PC-compatible, cloud-based t:connect Diabetes Management Application, rated #1 by insulin pump users in independent patient surveys.1
The original t:connect Application was designed with significant input from patients, placing the ability to monitor diabetes goals between clinic visits within their control. The simple, accessible reporting empowers and encourages patients to take an active role in their care. As a result, a significant number of Tandem pump users upload and view their data in the t:connect Application.2 More than half of Tandem pump users have logged into the t:connect Application in the past 90 days and upload three times per month on average.
The t:connect HCP Portal was developed based on information and feedback collected from hundreds of physicians, nurses, diabetes educators and office staff across the United States to streamline their use of the original t:connect Application and improve office efficiency. Healthcare providers can now upload data from a Tandem pump and blood glucose meter simultaneously, find patients quickly by either first or last name, set patient-specific ranges to quickly identify data that falls outside of goals, and more easily view, save and print reports. The t:connect Application is also cloud based, allowing access to previously uploaded patient data from any internet-connected computer in the U.S.
If you are a healthcare provider and would like to learn more about the t:connect HCP Portal, please talk to your local Tandem Representative or contact Customer Technical Support at (877) 801-6901.
About Tandem Diabetes Care, Inc.
Tandem Diabetes Care, Inc. (www.tandemdiabetes.com)
is a medical device company with an innovative, user-centric and
integrated approach to the design, development and commercialization of
products for people with diabetes who use insulin. The Company
manufactures and sells the t:slim X2™ Insulin Pump, the slimmest and
smallest durable insulin pump currently on the market, the t:flex®
Insulin Pump, the first pump designed for people with greater insulin
requirements, and the t:slim G4™ Insulin Pump, the first continuous
glucose monitoring-enabled pump with touch-screen simplicity. Tandem is
based in San Diego, California.
Follow Tandem Diabetes Care on Twitter @tandemdiabetes; use #tslimX2,
#tslimG4, #tflex, #tconnect, and $TNDM.
Follow Tandem Diabetes Care
on Facebook at www.facebook.com/TandemDiabetes.
Follow
Tandem Diabetes Care on LinkedIn at https://www.linkedin.com/company/tandemdiabetes.
Tandem Diabetes Care, t:connect and t:flex are registered trademarks,
and t:slim X2 and t:slim G4 are trademarks of Tandem Diabetes Care, Inc.
All
other trademarks are the property of their respective owners.
Forward Looking Statement
This press release contains
“forward-looking statements” within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the Securities
Exchange Act of 1934, as amended, that concern matters that involve
risks and uncertainties that could cause actual results to differ
materially from those anticipated or projected in the forward-looking
statements. These forward-looking statements relate to, among other
things the intended benefits of the t:connect HCP Portal. These
statements are subject to numerous risks and uncertainties, including
lack of market acceptance by healthcare providers; the potential that
newer products that compete with this product, or other technological
breakthroughs for the monitoring, treatment or prevention of diabetes
may render this product obsolete or less desirable; the Company’s
ability to support the commercial implementation and maintenance of the
t:connect HPC Portal; the Company’s ability to obtain regulatory
approvals for future products and product features generally; as well as
other risks identified in Tandem’s most recent Annual Report on Form
10-K, and other documents that Tandem files with the Securities and
Exchange Commission. Readers are cautioned not to place undue reliance
on these forward-looking statements, which speak only as of the date of
this release. Tandem undertakes no obligation to update or review any
forward-looking statement in this press release because of new
information, future events or other factors.
1 dQ&A USA Patient Connections Surveys, 2013-2016.
2
Data on file. Tandem Diabetes Care.
